Should I buy or sell Nuvation Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVB shares. View NUVB analyst ratings or view top-rated stocks .

What is Nuvation Bio's stock price target for 2024?

4 Wall Street analysts have issued 12-month price targets for Nuvation Bio's stock. Their NUVB share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 145.6% from the stock's current price. View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts .

How have NUVB shares performed in 2024?

Nuvation Bio's stock was trading at $1.51 on January 1st, 2024. Since then, NUVB shares have increased by 88.7% and is now trading at $2.85. View the best growth stocks for 2024 here .

When is Nuvation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NUVB earnings forecast .

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) issued its earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04.

What ETF holds Nuvation Bio's stock?

Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio.

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:NUVB

Nuvation Bio (NUVB) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free NUVB Stock Alerts

$2.85

-0.03 (-1.04%)

(As of 02:03 PM ET)

Compare

Today's Range: $2.80
▼
$2.92
50-Day Range: $1.62
▼
$3.96
52-Week Range: $0.95
▼
$4.16

Volume: 466,818 shs
Average Volume: 1.19 million shs
Market Capitalization: $621.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Nuvation Bio alerts:

Nuvation Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 145.6% Upside
$7.00 Price Target
Short Interest: Healthy
2.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.35) to ($0.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

Medical Sector

467th out of 930 stocks

Pharmaceutical Preparations Industry

216th out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Nuvation Bio has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.10% of the float of Nuvation Bio has been sold short.
Short Interest Ratio / Days to Cover
Nuvation Bio has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nuvation Bio has recently increased by 6.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nuvation Bio does not currently pay a dividend.
Dividend Growth
Nuvation Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVB.

3.0

News and Social Media Coverage

News Sentiment
Nuvation Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Nuvation Bio this week, compared to 1 article on an average week.
Search Interest
15 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
20 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 1,900% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvation Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.09% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nuvation Bio are expected to decrease in the coming year, from ($0.35) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvation Bio is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvation Bio is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvation Bio has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About Nuvation Bio Stock (NYSE:NUVB)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

NUVB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NUVB Stock News Headlines

April 13, 2024 | markets.businessinsider.com

Strategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline Prospects

April 10, 2024 | businesswire.com

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

April 16, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

March 31, 2024 | seekingalpha.com

Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal

March 28, 2024 | businesswire.com

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

March 27, 2024 | msn.com

BTIG upgrades Nuvation to buy, cites AnHeart acquisition

March 27, 2024 | msn.com

Nuvation Bio continues to surge as more upgrades follow after AnHeart deal

March 20, 2024 | finance.yahoo.com

NUVB Apr 2024 2.000 put

April 16, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

March 16, 2024 | finance.yahoo.com

NUVB Apr 2024 0.500 call

March 15, 2024 | msn.com

Nuvation Bio begins subject dosing in Phase I/II solid tumour trial

March 14, 2024 | businesswire.com

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

March 14, 2024 | baystreet.ca

Biotech Sector Advances in Pancreatic Cancer Research

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Nuvation Bio Amid Strong Financial Performance and Promising Clinical Progress

February 29, 2024 | finance.yahoo.com

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024 | businesswire.com

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 17, 2024 | finance.yahoo.com

Owning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),

January 8, 2024 | msn.com

FDA clears Nuvation to begin Phase 1/2 study for oncology drug

January 8, 2024 | finance.yahoo.com

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

January 8, 2024 | finance.yahoo.com

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

November 13, 2023 | finance.yahoo.com

Nuvation Bio Announces Departure of Chief Financial Officer

November 4, 2023 | benzinga.com

Nuvation Bio Stock (NYSE:NUVB) Earnings Dates and Earning Calls

November 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)

November 3, 2023 | msn.com

Nuvation Bio GAAP EPS of -$0.09 beats by $0.02

November 2, 2023 | finance.yahoo.com

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

November 2, 2023 | finance.yahoo.com

Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results

October 23, 2023 | finance.yahoo.com

One Nuvation Bio Insider Raised Their Stake In The Previous Year

See More Headlines

Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:NUVB
CUSIP: N/A
CIK: 1811063
Web: www.nuvationbio.com
Phone: 332-208-6102
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +145.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -12.21%
Return on Assets: -11.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 44.11
Quick Ratio: 44.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.76 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 218,050,000
Free Float: 139,353,000
Market Cap: $621.44 million
Optionable: Optionable
Beta: 1.36

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. David T. Hung M.D. (Age 66)
Founder, President, CEO & Director
Comp: $944.51k
Dr. David C. Hanley Ph.D. (Age 54)
Chief Technical Operations Officer
Comp: $586.04k
Mr. Moses Makunje (Age 45)
Principal Accounting Officer & Principal Financial Officer
Dr. Gary Hattersley Ph.D. (Age 57)
Chief Scientific Officer
Comp: $687.88k
Ms. Stacy Markel (Age 59)
Chief People Officer
Ms. Kerry A. Wentworth (Age 51)
Chief Regulatory Officer
Dr. David Liu M.D. (Age 54)
Ph.D., Chief Medical Officer
Ms. Colleen Sjogren
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NUVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVB shares.
View NUVB analyst ratings or view top-rated stocks.
What is Nuvation Bio's stock price target for 2024?: 4 Wall Street analysts have issued 12-month price targets for Nuvation Bio's stock. Their NUVB share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 145.6% from the stock's current price.
View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts.
How have NUVB shares performed in 2024?: Nuvation Bio's stock was trading at $1.51 on January 1st, 2024. Since then, NUVB shares have increased by 88.7% and is now trading at $2.85.
View the best growth stocks for 2024 here.
When is Nuvation Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NUVB earnings forecast.

How were Nuvation Bio's earnings last quarter?: Nuvation Bio Inc. (NYSE:NUVB) issued its earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04.
What ETF holds Nuvation Bio's stock?: Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio.
How do I buy shares of Nuvation Bio?: Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NUVB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nuvation Bio (NUVB) Stock Price, News & Analysis

Nuvation Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Nuvation Bio Stock (NYSE:NUVB)

NUVB Stock Price History

NUVB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NUVB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™